The Intention Architect today announced the launch of a new platform designed to bridge the gap between professional counseling and daily life by integrating structured, self-guided reflection into ...

The recent selling pressure in U.S. equity markets (SP500), (COMP:IND), (DJI) has little connection to geopolitical tensions and is not fundamentally driven, according to Matthew Mishkin, co-chief ...

The stock has briefly touched $200 a share before. Palantir's prior valuation could support a $200 price target based on earnings estimates. However, other considerations are at play. Leveraging ...

Data centers' enormous electricity demands are straining the U.S. power grid. Energy Transfer, Constellation Energy, and Enbridge are all benefiting from the AI market. Each of these energy company ...

On March 27, 2026, Reuters reported that as artificial intelligence expands, overburdened U.S. electricity grids force data center operators to reduce power consumption during peak demand. The ...

U.S. stocks continued to drift higher Monday morning after data showed that economic activity in the manufacturing sector expanded in January for the first time in 12 months. The latest ISM ...

In this article, we will look at 5 Stocks in Focus: Jim Cramer on NVIDIA, Callers’ Picks, and Recent AI Data Center Rally. Please visit 11 Stocks in Focus: Jim Cramer on NVIDIA, Callers’ Picks, and ...

Here are some of the stocks making headlines in midday trading. Entergy — The utility stock popped more than 8% after the firm announced a deal with Meta to support the hyperscale data center in ...

The frothy valuations that were daunting just a few months ago have already been dialed back quite a bit. Even so, most of the tech sector's stocks are in a holding pattern somewhere between being ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Ocugen (OCGN) shares lost ~12% in the premarket on Tuesday after the company announced 12-month data from a mid-stage trial for OCU410, its gene therapy for an eye disorder called geographic atrophy ...